| Patient | Duke Kahanamoku |
|---|---|
| Date of birth | 1890-08-24 |
| Identifiers | MRN HR-ML050-SYN-TD; SSN (made up) 000-50-6847 |
| Document date | 1957-03-30 |
| Author | Kawika Lindgren-Morrison, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review: echocardiogram, heart failure consultation and the diagnosis. [S]
Mr. Kahanamoku returns two weeks after intake and is seen the same day by Dr. Abernathy-Chen of heart failure cardiology after his echocardiogram this morning. At his wish, two members of his ʻohana joined the discussion with the cardiologist. On furosemide 40 mg he has lost 2.6 kg; his ankles swell less, and he now sleeps on one pillow. He is still breathless walking up a slope and has not been back in the water. He has had no chest pain, palpitations, fainting or lightheadedness. He took his last lisinopril dose this morning. The echocardiogram shows a weak heart muscle with an ejection fraction of 30% and an old scar at the front and tip of the heart. [S]
| Element | Detail |
|---|---|
| Since intake | Weight down 2.6 kg; less ankle swelling; one pillow |
| Function | Breathless walking uphill; NYHA class III |
| Echocardiogram | Ejection fraction 30%; thinned, akinetic anterior wall and apex; moderate functional mitral regurgitation |
| Last lisinopril dose | This morning |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Breathless walking uphill; less ankle swelling; no chest pain, palpitations or fainting |
| Respiratory | Negative | No cough; orthopnea resolved |
| Genitourinary | Negative | Passing more urine in the mornings |
| Musculoskeletal | Negative | No cramps |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 1952-06-21 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1952-06-21 to 1957-03-16 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1957-03-16 | active | S |
| Metoprolol tartrate 25 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 1952-06-21 to 1957-03-30 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1952-06-21 to 1957-03-30 | completed | S |
| Furosemide 40 mg oral tablet, one tablet every morning | One tablet every morning | Oral route | 1957-03-16 to 1957-04-27 | completed | S |
| Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril | One tablet twice daily | Oral route | 1957-03-30 to 1957-09-28 | completed | S |
| Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrate | One tablet twice daily with food | Oral route | 1957-03-30 to 1957-04-13 | completed | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking | One tablet daily, with sick-day rules | Oral route | 1957-03-30 | active | S |
| Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apart | Two infusions two weeks apart | Intravenous route | 1957-03-30 to 1957-04-13 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1957-03-30 | Body height | 185 | cm | S |
| 1957-03-30 | Body weight | 95 | kg | S |
| 1957-03-30 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 1957-03-30 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1957-03-30 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1957-03-30 | Heart rate | 86 | /min | S |
| 1957-03-30 | Respiratory rate | 18 | /min | S |
| 1957-03-30 | Body temperature | 36.6 | Cel | S |
| 1957-03-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1957-03-30 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1957-03-30 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1957-03-30 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1957-03-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M | 76 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1957-03-30 | Glucose [Mass/volume] in Serum or Plasma | 98 | mg/dL | 70-99 mg/dL | Normal | S |
| 1957-03-30 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.6-2.6 mg/dL | Normal | S |
| 1957-03-30 | Left ventricular Ejection fraction | 30 | % | 50-70% | Low | S |
Vital signs recorded on 1957-03-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Comfortable at rest; blood pressure 134/82, pulse 86; weight 95.0 kg, down 2.6 kg |
| Neck | Jugular venous pressure 3 cm above the sternal angle, down from 6 |
| Cardiovascular | Regular rhythm; displaced apex; soft S3; apical systolic murmur |
| Respiratory | Fine crackles at both bases only |
| Extremities | Trace ankle edema, from 2+ |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determined | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction. |
| Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1883 | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history. |
| Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosis | active | confirmed | I50.22 | S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime. |
| Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%) | active | confirmed | E61.1 | S — Synthetic finding at the heart failure workup. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and heart rate (seated and standing) | Every visit | Completed today | 134/82 mmHg, pulse 86 |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 95.0 kg (down 2.6); jugular venous pressure 3 cm; basal crackles; trace edema; NYHA III |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after starting or changing a diuretic, ARNI, MRA or SGLT2 inhibitor; then every three to six months | Completed today | Two weeks after furosemide: sodium 137, potassium 3.9, creatinine 1.08 mg/dL (eGFR 76), magnesium 1.9 |
| Imaging | Echocardiogram | At diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained change | Completed today | Ejection fraction 30%; thinned, akinetic anterior wall and apex; left ventricular end-diastolic diameter 62 mm; moderate functional mitral regurgitation |
| Examination | ECG (rhythm and QRS width) | At diagnosis and with change or device consideration | Up to date | At intake: sinus rhythm, old anterior Q waves, QRS 104 ms |
| Laboratory | NT-proBNP | At diagnosis; selectively for prognosis (not for titration) | Up to date | 2,450 pg/mL at intake |
| Laboratory | Initial workup (blood count, TSH, hemoglobin A1c, lipids, liver tests) | At diagnosis | Up to date | Hemoglobin 13.4, TSH 2.1, hemoglobin A1c 5.9%, LDL 92, ALT 28 at intake |
| Medication safety | Iron studies (ferritin, transferrin saturation) and intravenous iron | At diagnosis; after repletion and about yearly | Completed today | Ferritin 62 and transferrin saturation 16% at intake; ferric carboxymaltose 750 mg given today, second dose in two weeks |
| Medication safety | Guideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target doses | Every two weeks during titration | Completed today | Sacubitril-valsartan from 36 hours after the last lisinopril; carvedilol in place of metoprolol tartrate; empagliflozin; spironolactone next |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Up to date | 38 at intake; next in two weeks |
| Examination | Primary-prevention ICD evaluation (and CRT if QRS is wide) | After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarction | Due | Not before 90 days of optimized therapy; QRS 104 ms, so no CRT |
| Laboratory | Lipid panel | Four to twelve weeks after a statin change, then every three to twelve months | Ordered | LDL 92 mg/dL at intake; atorvastatin raised to 80 mg; panel due four to twelve weeks after the change |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Periodically | Up to date | PHQ-2 1 at intake |
| Referral | Cardiac rehabilitation for heart failure | When eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeks | Due | Not yet eligible: needs six weeks of stable therapy and six weeks after angiography |
| Self-management | Self-care: daily weights, sodium, sick-day rules and symptoms to report | Every visit | Completed today | Daily weights with a written plan; sodium plan; sick-day rules for empagliflozin |
| Examination | Vaccinations (pneumococcal, influenza, COVID-19, RSV) | Pneumococcal once; others yearly or per schedule | Completed today | PCV20 today; influenza, COVID-19 and RSV in the autumn |
| Self-management | Culturally safe care: ʻohana involvement as he chooses; his own healing practices | Every visit | Completed today | ʻOhana present at his wish; decisions his; lomilomi through Ke Ola Mamo offered |
| Referral | Heart failure cardiology consultation | At diagnosis | Completed today | Seen by Dr. Abernathy-Chen today |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026); Ke Ola Mamo: a Native Hawaiian Health Care System serving Oʻahu (medical care, lomilomi and community health workers) (2026)
Follow-up: Coronary angiography next week. Review in two weeks with a metabolic panel, the KCCQ-12 and the second iron infusion. Call for a weight gain of more than 1 kg in a day or 2 kg in a week, lightheadedness, or breathlessness at rest; call 911 for chest pain or fainting. Next scheduled visit 1957-04-13: two-week review after sacubitril-valsartan, carvedilol and empagliflozin: kidney function, potassium, angiography result and the next medicine. [S]